Editorial

Incrementally does it: multicolour imaging in polypoidal choroidal vasculopathy

Roderick O’Day MBBS\textsuperscript{1,2} and Sanjeewa S Wickremasinghe DMedSc FRANZCO\textsuperscript{2,3}

\textsuperscript{1}Ocular Oncology Service, Moorfields Eye Hospital and St Bartholomew’s Hospital, London, UK
\textsuperscript{2}Medical Retina Unit, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, Australia
\textsuperscript{3}Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia

Correspondence: Sanjeewa S Wickremasinghe, Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
Email: sanjeewa_w@hotmail.com

Funding sources / Financial disclosure: None
Conflict of interest: None

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ceo.13568
Advances in imaging technology over the past 20 years have driven improved understanding and treatment of retinal pathologies.

To be useful, a new imaging technique should achieve one of: 1) improve diagnostic accuracy; 2) provide accurate prognostic information; 3) monitor efficacy of treatment; or 4) advance our understanding of the pathophysiology of a disease. There are many successful examples of these. Characteristic OCT and fundus autofluorescence (FAF) changes in macular telangiectasia type 2 allows this condition to be diagnosed earlier and more accurately (1); the recent description of disorganisation of the retinal inner layers is proving to be an accurate predictor of response to anti-vascular endothelial growth factor (anti-VEGF) inhibitor treatment for diabetic macular oedema (2); OCT is the mainstay of monitoring efficacy of treatment of all intravitreal therapies, the most common being anti-VEGF injections for neovascular age-related macular degeneration (nvAMD) (3); and OCT has been instrumental in delineating the relatively recently described clinical entity of paracentral acute middle maculopathy and establishing that it is most likely caused by ischaemia of the deep retinal capillary plexus. (4)

Polypoidal choroidal vasculopathy (PCV) is a prime example of a condition that would benefit from better imaging technology to aid its diagnosis. PCV has a higher prevalence in Asian populations but is likely underdiagnosed in Caucasians and although it shares many features with nvAMD, it is generally thought to have a more favourable prognosis. (5) Despite this, the response to vascular endothelial growth factor inhibition is less predictable in PCV than nvAMD; and large subretinal haemorrhages are more common, which can result in significant retinal atrophy or subretinal fibrosis and irreversible vision loss. (6,7) High calibre longitudinal studies of the natural history of PCV are, however, lacking. Furthermore, due to under-diagnosis, it is likely that many studies of nvAMD have included patients with PCV in...
their cohorts. Consequently, an accurate understanding of the differences in natural history and treatment outcomes between PCV and nvAMD is not known.

In EVEREST II, combination therapy with photodynamic therapy (PDT) and ranibizumab was found to have better visual and anatomic outcomes as compared to ranibizumab monotherapy at 12 months. (8) Polyp closure was much higher in the combination group (70% vs 35%). (8) In the PLANET study, monotherapy with aflibercept was found to have non-inferior visual outcomes as compared to combined aflibercept and PDT in patients who did not respond to an initial course of aflibercept. (9) These studies certainly suggest a role for PDT in patients with centre-involving PCV, unlike the situation in nvAMD.

The difficulty for clinicians, especially those practicing in countries with supposedly lower prevalence of PCV, is to know when to investigate for the possible presence of PCV. The question as to timing is important. Should this be done prior to initiating anti-VEGF therapy, as is the routine case in many East Asian countries, or should further investigation be deferred until an unsatisfactory response is encountered following anti-VEGF monotherapy?

Indocyanine green angiography (ICGA) is the gold-standard for the diagnosis of PCV. (10) ICGA is an invasive, time-consuming test with potential side effects and can be difficult to interpret. In Australia, ICGA is almost exclusively offered in tertiary referral centres. This lack of availability limits the ability to accurately diagnose and manage patients with PCV. It is therefore imperative to find other less invasive and more widely available methods to do so.

Multimodal imaging techniques, consisting of colour fundus photography (CFP), OCT, fundus fluorescein angiography (FFA) and OCT angiography, have shown
encouraging results in accurately diagnosing PCV without the need for ICGA. (5,11-13) OCT is particularly useful at detecting shallow sub-RPE lesions, such as the 'double layer sign' which corresponds to branching vascular networks (BVN). The reported sensitivity and specificity ranged from 85 to 95% with ICGA as the comparator gold-standard technique in these studies. (5,11-13)

In their paper in this issue, Tan et al, examine the accuracy of using multicolour imaging at diagnosing PCV and nvAMD as compared to colour fundus photography (CFP). (14) This is the first report of this technique in PCV. Multicolour imaging is a false colour imaging technique that combines the reflectances of three scanning laser ophthalmoscopy wavelengths: infrared (815nm), green (518nm) and blue (486nm) on the Heidelberg Spectralis®. (Heidelberg Engineering GmbH, Heidelberg, Germany) The different wavelengths have variable penetrance of the retinal architecture, with the infrared being able to penetrate the retinal pigment epithelium (RPE) and be most useful in delineating the PCV lesions: polyps and branching vascular networks (BVNs). They found that the multicolour composite and infrared images had a greater sensitivity and specificity at detecting PCV lesions than CFP and that imaging was more reliable at detecting polyps than BVNs. The authors suggested that multicolour imaging could be used as an initial tool to assess patients with subretinal exudation to determine which would then need to progress to definitive assessment with ICGA. The authors did not assess how multicolour imaging correlated with OCT and OCT angiography. This would be a worthwhile future direction for research, as the strengths of these techniques at detecting PCV lesions are different. These could act synergistically and, potentially, obviate the need for ICGA to diagnose PCV. The patient population in this current study had a high proportion of patients of PCV. A degree of caution is warranted in extrapolating these results to other populations, such as Australian, with a lower prevalence of PCV.
Tan et al’s article (14) is the first report of multicolour imaging technology in PCV. It is certainly promising that a single image had a sensitivity and specificity of approximately 90% in diagnosing PCV lesions. Much work, however, remains to be done. Better detection rates of PCV, particularly in countries with low prevalence of the disease, will be crucial so that we can better understand the natural history and differences in treatment outcomes between patients with PCV and nvAMD.
REFERENCES


Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
O’Day, R; Wickremasinghe, SS

Title:
Incrementally does it: Multicolour imaging in polypoidal choroidal vasculopathy

Date:
2019-07-01

Citation:

Persistent Link:
http://hdl.handle.net/11343/286100